NTLA
Price
$24.75
Change
-$0.16 (-0.64%)
Updated
Oct 17 closing price
Capitalization
2.66B
19 days until earnings call
Intraday Buy/Sell Signals
VIR
Price
$5.78
Change
-$0.02 (-0.34%)
Updated
Oct 17 closing price
Capitalization
802.94M
12 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

NTLA vs VIR

Header iconNTLA vs VIR Comparison
Open Charts NTLA vs VIRBanner chart's image
Intellia Therapeutics
Price$24.75
Change-$0.16 (-0.64%)
Volume$3.84M
Capitalization2.66B
Vir Biotechnology
Price$5.78
Change-$0.02 (-0.34%)
Volume$1.07M
Capitalization802.94M
NTLA vs VIR Comparison Chart in %
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NTLA vs. VIR commentary
Oct 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a Hold and VIR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 18, 2025
Stock price -- (NTLA: $24.75 vs. VIR: $5.78)
Brand notoriety: NTLA and VIR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 64% vs. VIR: 77%
Market capitalization -- NTLA: $2.66B vs. VIR: $802.94M
NTLA [@Biotechnology] is valued at $2.66B. VIR’s [@Biotechnology] market capitalization is $802.94M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 0 FA rating(s) are green whileVIR’s FA Score has 1 green FA rating(s).

  • NTLA’s FA Score: 0 green, 5 red.
  • VIR’s FA Score: 1 green, 4 red.
According to our system of comparison, VIR is a better buy in the long-term than NTLA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 5 TA indicator(s) are bullish while VIR’s TA Score has 4 bullish TA indicator(s).

  • NTLA’s TA Score: 5 bullish, 4 bearish.
  • VIR’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than VIR.

Price Growth

NTLA (@Biotechnology) experienced а +0.94% price change this week, while VIR (@Biotechnology) price change was -0.34% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +15.88%, and the average quarterly price growth was +79.09%.

Reported Earning Dates

NTLA is expected to report earnings on Nov 06, 2025.

VIR is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($2.66B) has a higher market cap than VIR($803M). NTLA YTD gains are higher at: 112.264 vs. VIR (-21.253). NTLA has higher annual earnings (EBITDA): -501.87M vs. VIR (-586.27M). VIR has more cash in the bank: 606M vs. NTLA (460M). VIR (102M) and NTLA (103M) have identical debt. NTLA has higher revenues than VIR: NTLA (52.9M) vs VIR (14.4M).
NTLAVIRNTLA / VIR
Capitalization2.66B803M331%
EBITDA-501.87M-586.27M86%
Gain YTD112.264-21.253-528%
P/E RatioN/AN/A-
Revenue52.9M14.4M367%
Total Cash460M606M76%
Total Debt103M102M101%
FUNDAMENTALS RATINGS
NTLA vs VIR: Fundamental Ratings
NTLA
VIR
OUTLOOK RATING
1..100
7679
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
48
Fair valued
PROFIT vs RISK RATING
1..100
97100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
3549
P/E GROWTH RATING
1..100
10025
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (37) in the Biotechnology industry is in the same range as VIR (48) in the null industry. This means that NTLA’s stock grew similarly to VIR’s over the last 12 months.

NTLA's Profit vs Risk Rating (97) in the Biotechnology industry is in the same range as VIR (100) in the null industry. This means that NTLA’s stock grew similarly to VIR’s over the last 12 months.

NTLA's SMR Rating (98) in the Biotechnology industry is in the same range as VIR (98) in the null industry. This means that NTLA’s stock grew similarly to VIR’s over the last 12 months.

NTLA's Price Growth Rating (35) in the Biotechnology industry is in the same range as VIR (49) in the null industry. This means that NTLA’s stock grew similarly to VIR’s over the last 12 months.

VIR's P/E Growth Rating (25) in the null industry is significantly better than the same rating for NTLA (100) in the Biotechnology industry. This means that VIR’s stock grew significantly faster than NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTLAVIR
RSI
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
84%
Momentum
ODDS (%)
Bullish Trend 4 days ago
71%
Bullish Trend 1 day ago
73%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 11 days ago
74%
Declines
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
82%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
89%
Aroon
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
71%
View a ticker or compare two or three
Interact to see
Advertisement
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RMOYX26.43N/A
N/A
Victory RS Mid Cap Growth Y
SCIRX149.99N/A
N/A
Columbia Seligman Tech & Info R
WFDRX33.54N/A
N/A
Allspring SMID Cap Growth Fund - Cl R6
NDVRX15.88N/A
N/A
MFS New Discovery Value R1
VSGEX7.61N/A
N/A
Virtus SGA International Growth C

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-0.64%
VCYT - NTLA
69%
Closely correlated
+0.06%
BEAM - NTLA
63%
Loosely correlated
+0.74%
CRSP - NTLA
63%
Loosely correlated
+1.05%
RXRX - NTLA
56%
Loosely correlated
-7.86%
AXON - NTLA
55%
Loosely correlated
+2.84%
More

VIR and

Correlation & Price change

A.I.dvisor indicates that over the last year, VIR has been loosely correlated with SANA. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if VIR jumps, then SANA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VIR
1D Price
Change %
VIR100%
-0.34%
SANA - VIR
64%
Loosely correlated
-5.18%
CPRX - VIR
47%
Loosely correlated
+0.10%
AXON - VIR
47%
Loosely correlated
+2.84%
NRIX - VIR
43%
Loosely correlated
-1.89%
RLAY - VIR
42%
Loosely correlated
-0.31%
More